Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine

NACompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

Not specified

Study Completion Date

April 30, 1992

Conditions
HIV Infections
Interventions
DRUG

Zidovudine

DRUG

Didanosine

Trial Locations (18)

12203

Albany Med College / AIDS Treatment Ctr, Albany

19104

Univ of Pennsylvania / HIV Clinic, Philadelphia

23666

Dr Stephen L Green, Hampton

30308

AIDS Research Consortium of Atlanta, Atlanta

32806

VP Med Services / HHCS Research Institute Inc, Orlando

33316

G E Morey Jr, Fort Lauderdale

43699

Med College of Ohio, Toledo

48201

Harper Hosp, Detroit

53226

Milwaukee County Med Complex, Milwaukee

60141

Edward Hines Veterans Administration Hosp, Hines

67214

Univ of Kansas School of Medicine, Wichita

75235

Univ of Texas Southwestern Med Ctr of Dallas, Dallas

78284

Audie L Murphy Veterans Administration Hosp, San Antonio

84132

Univ of Utah School of Medicine, Salt Lake City

85724

Univ of Arizona / Health Science Ctr, Tucson

775550882

Univ TX Galveston Med Branch, Galveston

06510

Yale Univ Med School, New Haven

009275800

UPR School of Medicine, San Juan

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00002035 - Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine | Biotech Hunter | Biotech Hunter